Welcome to our dedicated page for Teladoc Health SEC filings (Ticker: TDOC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Carlos Nueno Plana filed a Form 144 to sell 20,165 common shares as restricted stock vests. The filing lists sale routing through Fidelity Brokerage Services LLC and notes the shares are tied to compensation and a vesting date of 02/27/2026. The filing also records a prior sale of 3,897 shares on 12/02/2025.
Teladoc Health outlines in its annual report how it operates a large-scale virtual care platform while remaining unprofitable. The company completed 17.1 million telehealth visits in 2025, serving approximately 102 million U.S. members across its Integrated Care and BetterHelp segments.
In 2025, Teladoc Health generated about 83% of consolidated revenue from recurring access fees, with the rest from visit fees and hardware and software for hospitals and health systems. It reported a net loss of $200.3 million for 2025 and an accumulated deficit of $16,430.2 million as of December 31, 2025, including non-cash goodwill impairments. The business depends heavily on a small group of large Clients, with the top five accounting for 19% of total revenue, and highlights regulatory, cybersecurity, competition, and privacy risks as key ongoing challenges.
Teladoc Health reported Fourth Quarter 2025 revenue of $642.3 million, roughly flat year-over-year, and a net loss of $25.1 million, or $0.14 per share. Adjusted EBITDA rose 12% to $83.8 million as Integrated Care offset softer BetterHelp performance.
For Full Year 2025, revenue declined 2% to $2.53 billion while net loss narrowed sharply to $200.3 million from $1.00 billion, helped by much lower goodwill impairments. Adjusted EBITDA fell 10% to $281.1 million. Operating cash flow was $294.4 million and free cash flow was $166.9 million. Guidance for 2026 calls for revenue of $2.47–$2.59 billion, adjusted EBITDA of $266–$308 million, and free cash flow of $130–$170 million, with Integrated Care growing modestly and BetterHelp expected to decline or remain roughly flat.
Smith Michael S reported acquisition or exercise transactions in this Form 4 filing.
Teladoc Health, Inc. director Michael S. Smith received a grant of 53,648 restricted stock units, each representing the right to receive one share of TDOC common stock. One-third of these units vest on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health, Inc. filed an initial insider ownership report for board member Michael S. Smith. This Form 3 filing establishes him as a reporting person under insider trading rules and provides the baseline disclosure of his existing relationship to the company as a director.
Teladoc Health expanded its board of directors and appointed Michael Smith as a new independent director, effective February 18, 2026. He was also named to the audit committee and the nominating and corporate governance committee, and is designated an “audit committee financial expert” under SEC and NYSE rules.
Smith brings more than three decades of experience in insurance and financial services, including senior roles at Voya Financial and Lincoln Financial, and currently serves as Executive Chairman of Talcott Financial Group. Teladoc Health also announced it will release fourth quarter 2025 results on February 25, 2026, followed by a conference call at 5:00 p.m. ET.
Teladoc Health, Inc. reported that long-serving director Thomas G. McKinley notified the company on February 8, 2026 of his intention to retire from the Board, effective February 20, 2026. The company states that Mr. McKinley is retiring for personal reasons and not due to any disagreement with the company on any matter.
Teladoc Health’s Chief Accounting Officer reported routine equity transactions in company stock. On 01/02/2026, restricted stock units converted into 2,083 shares of Teladoc Health common stock on a one-for-one basis. On 01/05/2026, the officer sold 758 shares at $7.145 per share to cover tax withholding obligations related to the vesting of restricted stock units.
After these transactions, the officer held 6,686 shares of Teladoc Health common stock directly and 14,584 restricted stock units. The filing notes that an earlier grant of 25,000 restricted stock units from October 1, 2024 vests one-third on the first anniversary of the grant date, with the remainder vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health director reports RSU conversion into common stock. On 12/19/2025, the reporting person converted 1,016 restricted stock units into an equal number of Teladoc Health common shares, increasing directly held common stock to 9,145 shares. A related derivative line shows 1,016 restricted stock units being settled for 1,016 common shares at an exercise price of $0, leaving 3,050 restricted stock units beneficially owned.
The filing notes that these restricted stock units were originally granted on September 20, 2023, in an award of 12,195 units that vest one‑third on the first anniversary of the grant date, with the remaining units vesting in eight substantially equal quarterly installments thereafter.
Teladoc Health, Inc. disclosed that board member J. Eric Evans plans to retire from its Board of Directors. He informed the company on December 11, 2025 that he will not stand for reelection at Teladoc Health’s 2026 Annual Meeting of Stockholders and will retire from the Board at the conclusion of that meeting.
Mr. Evans has served as a director since 2023. The company notes that he is retiring for personal reasons and that his decision is not due to any disagreement with Teladoc Health on any matter.